Current Price Disclosure cycle – 2025 October

Page last updated: 30 September 2025

The 2025 October cycle has a data collection period of 1 October 2024 to 31 March 2025.

Responsible persons must have disclosed brand data to the Price Disclosure Data Administrator (PDDA) by the deadline of 12 May 2025.

The reduction day is 1 October 2025.

Responsible persons should ensure that their authorised representatives keep their details up to date via the Health Products Portal, and sign up to the PBS Newsletter.

Contents

Outcomes of Price Disclosure calculations

The PDDA calculates weighted average disclosed prices (WADPs) to be provided to the Department of Health, Disability and Ageing. The Minister determines WADPs calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).

These outcomes have been published in the National Health (Weighted average disclosed price – October 2025 reduction day) Determination 2025 published on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their April 2025 PBS approved ex‑manufacturer price (AEMP) and the weighted average disclosed price (WADP) was below 10% or 30% (as applicable). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 31 March 2025 will also take the reduction on 1 October 2025 under section 99ADHA of the Act.

Please note an agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The deadline to lodge a dispute is 11 July 2025.

A list of pharmaceutical items scheduled for a price disclosure reduction and their weighted average disclosed prices is presented in the table below.

Legal Instrument Drug

Legal Instrument Form

Legal Instrument MoA

Brands of PI designated brands under 99ADHC (Y/N)

Floor Price

Price reduction applied in previous cycles (Y/N)

Average Unadjusted Price Reduction (UPR) at least 12.5% over 3 consecutive cycles (Y/N)

June 2025 AEMP

October 2025 AEMP

Percentage difference between June 2025 and October 2025 AEMP (%)

UPR threshold (%)

Calculations based on:
OWAPD = all brand data, or
GWAPD = originator brand data removed

Abacavir with lamivudine

Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg

Oral

Y

$40.30

N

Y

$40.30

$34.11

15.36%

10%

GWAPD

Ambrisentan

Tablet 10 mg

Oral

N

-

-

-

$1,381.53

$1,219.75

11.71%

10%

GWAPD

Ambrisentan

Tablet 5 mg

Oral

N

-

-

-

$1,381.53

$1,219.75

11.71%

10%

GWAPD

Aprepitant

Capsule 165 mg

Oral

N

-

-

-

$55.17

$49.52

10.24%

10%

GWAPD

Atovaquone with proguanil

Tablet containing atovaquone 250 mg with proguanil hydrochloride 100 mg

Oral

N

-

-

-

$51.22

$46.03

10.13%

10%

OWAPD

Bendamustine

Powder for injection containing bendamustine hydrochloride 100 mg

Injection

N

-

-

-

$124.07

$58.49

52.86%

10%

OWAPD

Bendamustine

Powder for injection containing bendamustine hydrochloride 25 mg

Injection

N

-

-

-

$31.02

$14.62

52.87%

10%

OWAPD

Bisoprolol

Tablet containing bisoprolol fumarate 10 mg

Oral

Y

$5.15

N

Y

$5.15

$4.40

14.56%

10%

GWAPD

Bisoprolol

Tablet containing bisoprolol fumarate 5 mg

Oral

Y

$4.12

N

Y

$4.12

$4.00

14.56%

10%

GWAPD

Bortezomib

Powder for injection 3.5 mg

Injection

N

-

-

-

$34.88

$20.47

41.31%

10%

OWAPD

Bortezomib

Solution for injection 3.5 mg in 1.4 mL

Injection

N

-

-

-

$34.88

$20.47

41.31%

10%

OWAPD

Bosentan

Tablet 125 mg (as monohydrate)

Oral

Y

$169.30

N

Y

$169.30

$117.53

30.58%

30%

OWAPD

Bosentan

Tablet 62.5 mg (as monohydrate)

Oral

Y

$169.30

N

Y

$169.30

$117.53

30.58%

30%

OWAPD

Cabergoline

Tablet 1 mg

Oral

N

-

-

-

$33.92

$24.82

26.83%

10%

OWAPD

Cabergoline

Tablet 2 mg

Oral

N

-

-

-

$45.46

$33.27

26.81%

10%

OWAPD

Cabergoline

Tablet 500 micrograms

Oral

N

-

-

-

$12.43

$9.10

26.79%

10%

OWAPD

Carbimazole

Tablet 5 mg

Oral

N

-

-

-

$9.62

$6.25

35.03%

10%

GWAPD

Dabigatran etexilate

Capsule 75 mg (as mesilate)

Oral

N

-

-

-

$10.33

$8.50

17.72%

10%

OWAPD

Dasatinib

Tablet 100 mg

Oral

N

-

-

-

$1,019.07

$365.62

64.12%

10%

GWAPD

Dasatinib

Tablet 20 mg

Oral

N

-

-

-

$618.71

$221.98

64.12%

10%

GWAPD

Dasatinib

Tablet 50 mg

Oral

N

-

-

-

$1,019.07

$365.62

64.12%

10%

GWAPD

Dasatinib

Tablet 70 mg

Oral

N

-

-

-

$1,261.67

$452.66

64.12%

10%

GWAPD

Dimethyl fumarate

Capsule (modified release) 240 mg

Oral

N

-

-

-

$392.81

$300.62

23.47%

10%

GWAPD

Donepezil

Tablet containing donepezil hydrochloride 10 mg

Oral

Y

$5.46

N

Y

$5.46

$4.10

24.91%

10%

GWAPD

Donepezil

Tablet containing donepezil hydrochloride 5 mg

Oral

Y

$5.46

N

Y

$5.46

$4.10

24.91%

10%

GWAPD

Enalapril with hydrochlorothiazide

Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg

Oral

Y

$4.99

N

Y

$4.99

$4.21

15.63%

10%

GWAPD

Entecavir

Tablet 0.5 mg (as monohydrate)

Oral

Y

$34.14

N

Y

$34.14

$26.35

22.82%

10%

OWAPD

Entecavir

Tablet 1 mg (as monohydrate)

Oral

Y

$55.52

N

Y

$55.52

$42.86

22.80%

10%

OWAPD

Ezetimibe

Tablet 10 mg

Oral

Y

$5.25

N

Y

$5.25

$4.35

17.14%

10%

GWAPD

Ezetimibe with simvastatin

Tablet 10 mg-10 mg

Oral

Y

$7.76

N

Y

$7.76

$6.20

20.10%

10%

GWAPD

Ezetimibe with simvastatin

Tablet 10 mg-20 mg

Oral

Y

$8.15

N

Y

$8.15

$6.51

20.12%

10%

GWAPD

Ezetimibe with simvastatin

Tablet 10 mg-40 mg

Oral

Y

$8.70

N

Y

$8.70

$6.95

20.11%

10%

GWAPD

Ezetimibe with simvastatin

Tablet 10 mg-80 mg

Oral

Y

$9.47

N

Y

$9.47

$7.56

20.17%

10%

GWAPD

Fingolimod

Capsule 500 micrograms (as hydrochloride)

Oral

N

-

-

-

$829.79

$695.70

16.16%

10%

OWAPD

Flecainide

Tablet containing flecainide acetate 100 mg

Oral

N

-

-

-

$15.98

$14.16

11.39%

10%

GWAPD

Flecainide

Tablet containing flecainide acetate 50 mg

Oral

N

-

-

-

$12.89

$11.42

11.40%

10%

GWAPD

Flucloxacillin

Powder for injection 1 g (as sodium monohydrate)

Injection

Y

$8.50

N

Y

$8.50

$7.47

12.12%

10%

OWAPD

Fluconazole

Capsule 100 mg

Oral

Y

$11.53

N

Y

$11.53

$9.55

17.17%

10%

GWAPD

Fluconazole

Capsule 200 mg

Oral

Y

$22.47

N

Y

$22.47

$18.62

17.13%

10%

GWAPD

Fluconazole

Capsule 50 mg

Oral

Y

$5.93

N

Y

$5.93

$4.91

17.20%

10%

GWAPD

Fosaprepitant

Powder for I.V. infusion 150 mg

Injection

N

-

-

-

$69.23

$58.22

15.90%

10%

OWAPD

Ganirelix

Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe

Injection

N

-

-

-

$22.10

$18.53

16.15%

10%

GWAPD

Glipizide

Tablet 5 mg

Oral

N

-

-

-

$7.51

$6.22

17.18%

10%

OWAPD

Icatibant

Injection 30 mg (as acetate) in 3 mL single use pre-filled syringe

Injection

N

-

-

-

$579.16

$420.88

27.33%

10%

OWAPD

Imatinib

Capsule 100 mg (as mesilate)

Oral

Y

$124.56

N

Y

$124.56

$80.03

35.75%

30%

GWAPD

Imatinib

Capsule 400 mg (as mesilate)

Oral

Y

$249.11

N

Y

$249.11

$160.05

35.75%

30%

GWAPD

Imatinib

Tablet 100 mg (as mesilate)

Oral

Y

$124.56

N

Y

$124.56

$80.03

35.75%

30%

GWAPD

Imatinib

Tablet 400 mg (as mesilate)

Oral

Y

$249.11

N

Y

$249.11

$160.05

35.75%

30%

GWAPD

Indapamide

Tablet containing indapamide hemihydrate 1.5 mg (sustained release)

Oral

Y

$6.24

N

Y

$6.24

$5.07

18.75%

10%

GWAPD

Isotretinoin

Capsule 10 mg

Oral

Y

$18.36

N

Y

$18.36

$15.89

13.45%

10%

GWAPD

Isotretinoin

Capsule 20 mg

Oral

Y

$14.31

N

Y

$14.31

$12.39

13.42%

10%

GWAPD

Lacosamide

Tablet 100 mg

Oral

N

-

-

-

$16.57

$11.42

31.08%

10%

GWAPD

Lacosamide

Tablet 150 mg

Oral

N

-

-

-

$24.85

$17.12

31.11%

10%

GWAPD

Lacosamide

Tablet 200 mg

Oral

N

-

-

-

$132.53

$91.30

31.11%

10%

GWAPD

Lacosamide

Tablet 50 mg

Oral

N

-

-

-

$8.28

$5.70

31.16%

10%

GWAPD

Lenalidomide

Capsule 10 mg

Oral

N

-

-

-

$548.44

$400.72

26.93%

10%

OWAPD

Lenalidomide

Capsule 15 mg

Oral

N

-

-

-

$660.53

$482.63

26.93%

10%

OWAPD

Lenalidomide

Capsule 20 mg

Oral

N

-

-

-

$844.46

$505.16

40.18%

10%

OWAPD

Lenalidomide

Capsule 25 mg

Oral

N

-

-

-

$864.20

$631.44

26.93%

10%

OWAPD

Lenalidomide

Capsule 5 mg

Oral

N

-

-

-

$418.64

$305.88

26.93%

10%

OWAPD

Letrozole

Tablet 2.5 mg

Oral

Y

$9.72

N

Y

$9.72

$7.55

22.33%

10%

GWAPD

Levetiracetam

Tablet 250 mg

Oral

Y

$8.95

N

Y

$8.95

$7.18

19.78%

10%

GWAPD

Levetiracetam

Tablet 500 mg

Oral

Y

$14.91

N

Y

$14.91

$11.96

19.79%

10%

GWAPD

Mycophenolic acid

Capsule containing mycophenolate mofetil 250 mg

Oral

Y

$25.48

N

Y

$25.48

$19.20

24.65%

10%

GWAPD

Mycophenolic acid

Tablet containing mycophenolate mofetil 500 mg

Oral

Y

$25.46

N

Y

$25.46

$19.18

24.67%

10%

GWAPD

Pirfenidone

Tablet 267 mg

Oral

N

-

-

-

$150.26

$123.41

17.87%

10%

OWAPD

Pirfenidone

Tablet 801mg

Oral

N

-

-

-

$450.80

$370.24

17.87%

10%

OWAPD

Plerixafor

Injection 24 mg in 1.2 mL

Injection

N

-

-

-

$4,016.84

$1,129.54

71.88%

10%

GWAPD

Pomalidomide

Capsule 1 mg

Oral

N

-

-

-

$621.91

$430.49

30.78%

10%

OWAPD

Pomalidomide

Capsule 2 mg

Oral

N

-

-

-

$1,108.61

$767.38

30.78%

10%

OWAPD

Pomalidomide

Capsule 3 mg

Oral

N

-

-

-

$1,662.92

$1,151.07

30.78%

10%

OWAPD

Pomalidomide

Capsule 4 mg

Oral

N

-

-

-

$2,217.22

$1,534.76

30.78%

10%

OWAPD

Rasagiline

Tablet 1 mg (as mesilate)

Oral

N

-

-

-

$18.67

$14.57

21.96%

10%

GWAPD

Riluzole

Tablet 50 mg

Oral

Y

$113.30

N

Y

$113.30

$89.04

21.41%

10%

GWAPD

Risperidone

Tablet 2 mg

Oral

Y

$8.90

N

N

$8.90

$6.22

30.11%

30%

OWAPD

Risperidone

Tablet 3 mg

Oral

Y

$13.73

N

N

$13.73

$9.60

30.08%

30%

OWAPD

Risperidone

Tablet 4 mg

Oral

Y

$18.52

N

N

$18.52

$12.95

30.08%

30%

OWAPD

Rivaroxaban

Capsule 15 mg

Oral

N

-

-

-

$32.78

$26.99

17.66%

10%

OWAPD

Rivaroxaban

Capsule 20 mg

Oral

N

-

-

-

$32.38

$26.66

17.67%

10%

OWAPD

Rivaroxaban

Tablet 10 mg

Oral

N

-

-

-

$18.62

$15.33

17.67%

10%

OWAPD

Rivaroxaban

Tablet 15 mg

Oral

N

-

-

-

$32.78

$26.99

17.66%

10%

OWAPD

Rivaroxaban

Tablet 2.5 mg

Oral

N

-

-

-

$32.87

$27.07

17.65%

10%

OWAPD

Rivaroxaban

Tablet 20 mg

Oral

N

-

-

-

$32.38

$26.66

17.67%

10%

OWAPD

Tetrabenazine

Tablet 25 mg

Oral

N

-

-

-

$201.97

$179.49

11.13%

10%

GWAPD

Vinorelbine

Capsule 20 mg (as tartrate)

Oral

N

-

-

-

$46.05

$38.18

17.09%

10%

GWAPD

Vinorelbine

Capsule 30 mg (as tartrate)

Oral

N

-

-

-

$69.47

$57.59

17.10%

10%

GWAPD

Zoledronic acid

Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL

Injection

Y

$59.56

N

Y

$59.56

$45.72

23.24%

10%

GWAPD

Flow-on price disclosure reductions

A list of brands of pharmaceutical items that will be subject to an automatic flow-on price disclosure reduction under section 99ADHB of the National Health Act 1953 on 1 October 2025 is available in the Pricing-Combination-Flow-on-Price-Reductions-FED-1-Oct-2025 (Excel 12KB).

Sponsors are able to apply for Ministerial discretion for these reductions to be reduced or not apply. For more information see Ministerial Discretion.

Indicative prices of brands scheduled for a price disclosure reduction

The indicative prices for brands scheduled for price disclosure reductions in this cycle will be published to assist responsible persons and other stakeholders.

Indicative prices are not published for any medicines that are:

  • not taking a price disclosure reduction in this cycle;
  • new brands after the date of publication;
  • brands with other price changes on the reduction day.

Indicative prices reports for non-EFC items can be downloaded below:

Indicative prices reports for EFC items can be downloaded below:

Confirmed prices of brands scheduled for a price disclosure reduction

The Confirmed Prices Report outlines the approved ex‑manufacturer prices for brands scheduled to take a price disclosure reduction. The reports for the 2025 October Cycle can be downloaded below.

Brand price reductions and savings to patients

The Brand Price Reductions and Savings to Patients Report outlines the price disclosure reductions per brand and potential savings to non-concessional patients from 1 October 2025. This information is made available to assist patients understand how much they may save on their PBS medicines.

The report does not include any brands of medicines that have other price changes, or brands that are new to the PBS on the reduction day.

The brand price reductions report for the 2025 October cycle can be downloaded below.